Literature DB >> 20840338

The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables.

A S Lawrie1, L Green, M T Canciani, I J Mackie, F Peyvandi, M A Scully, S J Machin.   

Abstract

BACKGROUND: Octapharma PPGmbH has recently modified its manufacturing process for solvent/detergent-treated plasma to incorporate a prion reduction step, in which a 3 log reduction has been demonstrated. The current study was undertaken to assess the impact of this procedure on haemostatic variables in the new product OctaplasLG in comparison with standard Octaplas.
METHODS: Production batches of standard Octaplas (n=4) and OctaplasLG (n=16) were assessed for levels of coagulation factors, physiological protease inhibitors, markers of activation and procoagulant microparticles. Global haemostasis was assessed by a thrombin generation test (TGT) and rotational thromboelastometry (ROTEM).
RESULTS: Mean levels of factors: II, V, VII, IX, X, XI, XII and XIII, VWF:Ag, antithrombin, protein C and free protein S were all >75 u/dl. ADAMTS-13 activity levels were normal. Factor VIII and VWF:RCo were >55 u/dl. TGT and ROTEM were similar in both preparations, and microparticles were present at negligible levels. Two units of OctaplasLG had slightly elevated levels of Prothrombin Fragments 1+2, but D-Dimer and thrombin-antithrombin complexes were normal in all batches.
CONCLUSION: These studies indicate that the affinity chromatography procedure used in OctaplasLG does not appear to adversely affect the proven haemostatic quality of Octaplas, while offering a selective reduction in the concentration of pathological prion proteins.
© 2010 The Author(s). Vox Sanguinis © 2010 International Society of Blood Transfusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840338     DOI: 10.1111/j.1423-0410.2010.01346.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

1.  Thawing of Pooled, Solvent/Detergent-Treated Plasma octaplasLG®: Validation Studies Using Different Thawing Devices.

Authors:  Andrea Heger; Katharina Pock; Jürgen Römisch
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

Review 2.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

3.  Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma.

Authors:  Håkon Haugaa; Eli Taraldsrud; Hans Christian Nyrerød; Tor Inge Tønnessen; Aksel Foss; Bjarte G Solheim
Journal:  Clin Med Res       Date:  2014-01-10

Review 4.  Quality Assessment of Established and Emerging Blood Components for Transfusion.

Authors:  Jason P Acker; Denese C Marks; William P Sheffield
Journal:  J Blood Transfus       Date:  2016-12-14

Review 5.  Management of thrombotic thrombocytopenic purpura: current perspectives.

Authors:  Piers Blombery; Marie Scully
Journal:  J Blood Med       Date:  2014-02-05

6.  Resuscitation of Endotheliopathy and Bleeding in Thoracic Aortic Dissections: The VIPER-OCTA Randomized Clinical Pilot Trial.

Authors:  Jakob Stensballe; Annette G Ulrich; Jens C Nilsson; Hanne H Henriksen; Peter S Olsen; Sisse R Ostrowski; Pär I Johansson
Journal:  Anesth Analg       Date:  2018-10       Impact factor: 5.108

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.